Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mirdametinib by SpringWorks Therapeutics for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis): Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated)...
SW-682 by SpringWorks Therapeutics for Solid Tumor: Likelihood of Approval
SW-682 is under clinical development by SpringWorks Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
SW-682 by SpringWorks Therapeutics for Malignant Mesothelioma: Likelihood of Approval
SW-682 is under clinical development by SpringWorks Therapeutics and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase...
Mirdametinib by SpringWorks Therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease): Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Pre-Registration for Neurofibromatoses Type I (Von Recklinghausen's Disease). According...
Mirdametinib by SpringWorks Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of SpringWorks Therapeutics's BGB-3245?
BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Metastatic Colorectal Cancer. According...
Mirdametinib by SpringWorks Therapeutics for Low-Grade Glioma: Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Low-Grade Glioma. According to GlobalData, Phase...